

English translation for information purposes only. If there are differences between the English translation and the Swedish original, the Swedish text will take precedence.



THE BOARD OF DIRECTORS' PROPOSAL FOR A RESOLUTION ON AN ISSUE AUTHORIZATION

The Board of Directors proposes that the General Meeting resolves on an issue authorization for the Board of Directors mainly as set out below.

The Board of Directors shall be authorized to, on one or more occasions until the next Annual General Meeting, resolve on issue of new shares and/or warrants and/or convertible bonds.

An issue may be decided with or without regard of the shareholders' pre-emption rights. Following this authorization, a total maximum number of shares equivalent to 10 per cent of the total number of outstanding shares in the company on the date when the authorization is utilised for the first time may be issued in new share issues, by utilising the warrants and/or through the conversions of convertible bonds (this does not prevent warrants or convertible bonds from being combined with conversion terms which, if applied, may result in a different number of shares).

The authorization shall include the right to resolve on issue with cash payment, payment by contribution in kind or payment by way of set-off, and otherwise subject to conditions as set out in Chapter 2, Section 5, second paragraph 1–3 and 5 of the Swedish Companies Act.

The Board of Directors, or a person appointed by the Board of Directors, shall have the right to decide on such minor changes to the General Meeting's resolution that may be necessary in connection with registration of the resolution with the Swedish Companies Registration Office or due to other formal requirements.

A resolution according to the Board of Directors' proposal above is valid only if supported by shareholders holding at least two-thirds (2/3) of both the votes cast and the shares represented at the General Meeting.

Örnsköldsvik in April 2026
Clavister AB (publ)
The Board of Directors